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Abstract
Background: There is a need for non-invasive parameters that are sensitive to the development of the bronchiolitis
obliterans syndrome (BOS) in lung transplantation (LTx) patients. We studied whether the pulmonary diffusing
capacity for inhaled nitric oxide is capable of detecting BOS stages.
Methods: Sixty-one LTx patients were included into this cross-sectional study (19/29/7/3/3 in BOS stages 0/0-p/1/2/
3). For analysis stages 0/0-p versus 1/2/3 (“BOS binary-early”), and stages 0/0-p/1 versus 2/3 (“BOS binary-late”) were
summarized. Measurements of the combined diffusing capacity for nitric oxide (DLNO) and carbon monoxide
(DLCO) were compared with spirometry and bodyplethysmography, and their relative importance was evaluated
by discriminant analysis.
Results: Regarding the recognition of “BOS binary-early”, among spirometric parameters forced expiratory volume
in 1 s (FEV1) was best, among bodyplethysmographic parameters airway resistance, and among diffusing
parameters DLNO. Regarding “BOS binary-late”, DLNO was inferior to bodyplethysmographic parameters.
Conclusion: Although the study comprised only measurements at a single time point and no follow-up, DLNO
outperformed FEV1, the time course of which is used in detecting BOS. Together with its pathophysiological
plausibility, this result suggests that the measurement of DLNO, possibly over time, could be an easily applicable
tool for the monitoring of LTx patients and should be evaluated in larger studies.
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Background
Lung transplantation (LTx) is an established therapeutic
option to increase survival rates and improve quality of
life in selected end-stage lung disease patients [1]. Despite
increased survival rates, lung transplant recipients still
have a poor prognosis compared with other organ trans-
plant patients [1]. Long-term survival is limited by the oc-
currence of chronic lung allograft dysfunction (CLAD), an
umbrella term used to describe various pathophysiological
processes affecting the allograft [2], among them bron-
chiolitis obliterans syndrome (BOS), the most common
form of CLAD, and less frequently restrictive allograft
syndrome (RAS), and/or a combination of the two [3]. As
the detection of BOS enables immediate therapeutic inter-
vention, early diagnosis is essential.
The main clinical finding of BOS is an irreversible
airway obstruction with a persistent (≥3 weeks) reduc-
tion of forced expiratory volume in 1 s (FEV1) [4],
without evidence of acute infection, acute cellular and/
or antibody-mediated rejection and other factors [5, 6].
The classification covers BOS-0 (no BOS), BOS-0-p
(potential BOS), and BOS 1–3, based on increasing air-
way obstruction (FEV1) compared with the best-ever
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value post-transplantation. Moreover, a reduction in the
mean forced expiratory flow during the middle half of
forced vital capacity (FEF25–75) is used as an early marker
[4, 7]. FEV1 is an easily measurable but non-specific par-
ameter, which is unlikely to fully reflect the situation in
the lung periphery, where BOS originates [8]. The fact that
BOS is characterized by an abnormal remodelling of ter-
minal bronchioles, leading to airflow limitation of the
small airways [9], raises the question whether other lung
parameters could provide more detailed information. It is
known that total lung capacity (TLC) and the ratio of
TLC and residual volume (RV) are predictors of CLAD
and can help to identify high-risk patients [10]. Prior in-
vestigations from our group demonstrated that elevated
levels of exhaled nitric oxide (FeNO) could predict the de-
velopment of BOS in LTx patients and also could be an
early marker of deterioration in patients with or without
pre-existing functional impairment [11]. The data also
showed that a marked increase in follow-up FeNO mea-
surements could identify patients at risk for an unfavour-
able course, whereas stable LTx recipients showed a
significantly lower individual variation in FeNO values
[11]. Cameli et al. [12] investigated the role of exhaled NO
(eNO) and carbon monoxide (eCO) as markers of pul-
monary inflammation associated with acute graft rejection
and lung infection in LTx patients and found higher values
of FeNO and in particular a higher alveolar concentration
of nitric oxide (CalvNO) in LTx patients with BOS com-
pared to non-BOS patients [12]. This indicates that alveo-
lar markers might be suitable for detecting BOS, as airway
inflammation and remodelling of the small airways in LTx
patients with BOS could be associated with alveolar
changes such as elevated levels of peripheral eNO and
CalvNO [12]. Thus, gas-exchange parameters are also
candidates for detecting the malfunction of peripheral
structural changes. For this purpose the differentiation
from a capillary disorder would be helpful, and this task
could be performed by the diffusing capacity for nitric
oxide (DLNO), especially in combination with that for
carbon monoxide (DLCO). This combination has been
evaluated in various lung diseases but is not yet part of
clinical routine [13, 14].
The comparison of DLNO and DLCO allows for the
differentiation of lung components affected by the lung
disease, since the affinity for NO to hemoglobin is much
higher compared with that of CO [15]. Therefore, NO up-
take is largely unaffected by pulmonary capillary blood
volume (Vcap), in contrast with CO [16, 17], while the dif-
fusion resistance (membrane factor, DMCO) is similar for
both gases. DLNO can therefore be used to assess the
membrane factor, and in combination with DLCO the
Vcap. This allows for the differentiation between a thick-
ened alveolar capillary membrane and reduced blood flow
which is not possible by DLCO alone [18]. In case of
membrane thickening both DLCO and DLNO would be
affected, but DLNO stronger, while in case of a reduced
alveolar volume (VA) or a reduced Vcap, DLCO would
decrease more than DLNO [19]. Although BOS has an
obstructive component, it could also be associated with a
transport disorder of the alveolar membrane.
Based on these considerations, the aim of this investiga-
tion was to reveal whether the non-invasive measurement
of DLNO and DLCO is capable of an early detection of
BOS in LTx recipients.
Methods
Study population
This cross-sectional study was performed at the Depart-
ment of Internal Medicine V and the Institute and Out-
patient Clinic for Occupational, Social and Environmental
Medicine at the Ludwig Maximilian University of Munich,
Germany. The cohort was recruited through the out-
patient and inpatient sectors. A patient was enrolled in
the cohort if he or she fulfilled the following inclusion cri-
teria: (a) the patient was the recipient of a LTx performed
at the study center, and (b) the patient expressed his or
her willingness to participate in individually planned
follow-up assessments; and if the patient did not fulfill any
of the following exclusion criteria: (a) acute infections, (b)
high levels of physical exertion or food intake prior to the
measurements, (c) nicotine abuse on the day of measure-
ments, or (d) physical impairment resulting in an inability
to perform two valid and reproducible DLNO-DLCO
measurements [13]. All assessments were approved by the
local ethics committee (Ludwig Maximilian University of
Munich, Germany) and all patients gave their written in-
formed consent.
Assessments
Patients underwent a panel of assessments in order to
collect clinical characteristics and functional status. The
following parameters were recorded: height, weight, date
of birth, lung disease which led to LTx, date of transplant-
ation, type of transplantation (single LTx (SLTx), bilateral
LTx (BLTx)), BOS stage, allergies, past medication, date of
last food intake, acute respiratory infections, and smoking
history.
Measurements combined diffusing capacity (DLNO-DLCO)
Simultaneous measurements of DLNO, DLCO and
VA were performed using the single-breath method
(MasterScreen™ PFT Pro, Jaeger, CareFusion, Hoechberg,
Germany). Although the study was performed prior to the
recommendations of the American Thoracic Society and
European Respiratory Society, [20] the study was in ac-
cordance with their standards. After careful instruction,
patients performed three measurements at a breath-hold
time of 8 s [21, 22] with at least five-minute resting
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intervals in between maneuvers to assure elimination of
the test gas from the lungs. Incorrect measurements were
repeated, to gain at least two plausible measurements, the
mean of which was included in the further analyses. Using
a breath-hold time of 8 s, excellent test-retest reliability
has been reported for combined DLNO-DLCO measure-
ments in patients with cystic fibrosis [21]. The test gas
comprised a mixture of 0.28% carbon monoxide (CO),
600 mg/m3 nitric oxide (NO) and 9.5% helium. Again, the
measurements of VA, DLCO and DLNO satisfied the
technical standards proposed by Zavorsky et al. [23],
although the study was performed prior to publication of
these recommendations. The transfer coefficients for
nitric oxide (KNO) and carbon monoxide (KCO) were
calculated by dividing DLNO and DLCO through VA,
while the alveolar-capillary membrane diffusing capacity
for carbon monoxide (DMCO) and Vcap were derived as
proposed [13]. Percent predicted values for DLNO and
DLCO were calculated according to Zavorsky et al. [23]
based on previous work by Roughton et al. [24] and
Guènard et al. [16], and DLCO was adjusted for
hemoglobin [13, 17, 18].
In addition to DLNO and DLCO, conventional pa-
rameters of spirometry and bodyplethysmography were
collected [25, 26]. For analysis the forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC)
were used, as well as intrathoracic gas volume (ITGV),
residual volume (RV), total lung capacity (TLC), airway
resistance (Raw) and specific airway resistance (sRaw).
Percent predicted values for spirometry and bodyplethys-
mography were taken from the Global Lung Initiative
[27], or the European Coal and Steel Community (ECCS)
[28], respectively. Furthermore, routine laboratory param-
eters including hemoglobin, sodium, potassium, creatinine
and CRP values were collected.
Statistical analysis
For data description, mean values and standard deviations
(SD) were used. Comparisons between groups were per-
formed using non-parametric tests, especially the
Mann-Whitney-U test and the Kruskal-Wallis test, as well
as chi-squared statistics for categorical data. To evaluate
the value of the combined diffusing capacity for BOS rec-
ognition, patients were grouped into binary categories ac-
cording to their BOS-stage. For the purpose of early
diagnosis (“BOS binary-early”), stages 0 and 0-p were
combined and compared with stages 1–3. To reveal
whether it was possible to differentiate an initial diagnosis
from progression, stages 0, 0-p and 1 were combined ver-
sus the combination of stages 2 and 3; this classification
was termed “BOS-binary-late”. The relationship between
BOS groups and predictors was analyzed by means of lin-
ear discriminant analysis in order to identify the best pa-
rameters to differentiate between the respective groups.
We used an approach with forward selection. The results
were checked by logistic regression analyses performed in
an analogous manner. The level of statistical significance
(alpha) was set at 0.05 for all analyses. Statistical analyses
were performed with SPSS Statistics 23 (IBM Corp.,
Armonk, NY, USA).
Results
Patient population
Sixty-four patients were screened for the study. Three
patients were excluded because they were not capable
of performing valid diffusing capacity measurements.
Therefore, 61 patients (29 males, 32 females; mean ±
SD age 50.8 ± 13.7 years) were included in the analysis.
BLTx had been performed in 19/23 male/female pa-
tients. SLTx and BLTx patients showed no significant
differences in anthropometric characteristics and the
time between LTx and measurements, while BLTx pa-
tients were younger (45.8 ± 13.0 years, p < 0.001) than
SLTx patients (61.8 ± 7.5 years).
BOS stages and pre-existing conditions
Idiopathic lung fibrosis (IPF) was the reason for trans-
plantation in 22 patients. Following the official American
Thoracic Society Statement, IPF was defined as chronic,
progressive fibrosing interstitial pneumonia of unknown
cause occurring primarily in adults, limited to the lungs,
with radiological signs and/or histopathologic patterns
consistent with usual interstitial pneumonia [29]. Further
reasons for transplantation were COPD with emphysema
in 16 patients (2 with alpha-1-antitrypsine deficiency),
cystic fibrosis in 11 patients, three patients suffered from
sarcoidosis, while the remaining 9 patients formed a
heterogeneous group of diagnoses, including systemic
lupus erythematosis, lymphangioleiomyomatosis, silicosis,
Kartagener syndrome, or hypersensitivity pneumonitis
alveolitis. There was no significant association between
BOS-stages and the pre-existing lung disease.
BOS stages and patients’ characteristics
The average interval between LTx and time of measure-
ment was 4.3 ± 3.7 years. Nineteen patients were diag-
nosed as BOS-0, 29 patients as BOS 0-p, 7 as BOS 1, 2
as BOS 2, and 3 as BOS 3 (Table 1). There were no sig-
nificant differences for age and BMI (Table 1) between
BOS stages, when using the full classification or the
binary groups. There was a significant difference in the
number of years after LTx (p = 0.001), with the shortest
period of time in BOS 0 and the longest in BOS 3There
were no significant differences in the laboratory param-
eters hemoglobin, creatinine, CRP, sodium and potas-
sium across the BOS-stages.
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BOS stages, lung function and combined DLNO-DLCO
Pulmonary function characteristics for all patients (n = 61)
are shown in Tables 2 and 3. Increasing BOS stages
were significantly associated with higher values of Raw
and sRAw, and with lower values of FEV1 and FEV1/
FVC (p < 0.05 each); RV/TLC and ITGV/TLC were bor-
derline to non-significant (p = 0.055 each). Higher BOS
stages were also significantly linked to lower values of
DLCO, DLNO, and DMCO (p < 0.05 each). The discrim-
ination capability of DLNO % predicted versus FEV1%
predicted is shown in Fig. 1.
Recognition of early BOS
The comparison of pulmonary function parameters be-
tween the two groups BOS 0/0-p and BOS 1–3 (BOS
binary-early) showed lower values of FEV1 and higher
values of RV/TLC (Mann-Whitney-U test, p < 0.05 each).
When comparing diffusing capacity parameters between
groups, DLCO, DLNO, VA and DMCO turned out to be
significantly reduced in the BOS 1–3 group, either re-
garding the absolute or % predicted values (Mann-Whit-
ney-U test, p < 0.05). The individual data for FEV1 and
DLNO are shown in Fig. 2.
In a discriminant analysis using the spirometric pa-
rameters only, FEV1% predicted was identified as the
major variable separating the two BOS groups “BOS
binary-early” (specificity 60.4%, sensitivity 61.5%, posi-
tive predictive value 60.7%). It should be noted that the
numbers of patients in both groups were unbalanced
(n = 48 versus n = 13), and that sensitivity and specifi-
city were low. Likewise, when performing the analysis
with bodyplethysmographic parameters only, Raw was
the only significant variable discriminating between the
two BOS groups (specificity 70.8%; sensitivity 46.2%,
positive predictive value 65.5%). When repeating the
discriminant analysis with data from both spirometry and
bodyplethysmography, Raw again remained as major vari-
able separating the two groups “BOS binary-early”, thus
the combination of data had no additive value.
When the analysis was performed with all directly
measured and derived parameters of the combined
diffusing capacity, DLNO % predicted remained as only
significant variable separating the two groups “BOS
binary-early” (specificity 64.6%, sensitivity 69.2%, positive
predictive value 65.6%). Since the combined measure-
ment allows for the separation of membrane factor and
Vcap, in a separate analysis only the derived parameters
were tested, which revealed the membrane factor
DMCO % predicted as only significant variable for “BOS
binary-early” (positive predictive value 60.7%); Vcap
played no role. As DMCO depends on DLNO, this result
is plausible.
Finally, to compare the predictive value between the
three lung function domains described above, a discrim-
inant analysis with the best parameters from each; i.e.,
FEV1, DLNO or DMCO (each in % predicted), and Raw
was performed. In this analysis DLNO % predicted was
the dominant and only significant variable discriminating
between no BOS and “BOS binary-early” (positive predict-
ive value as above: 65.6%). This finding demonstrated that
DLNO carried more information than spirometry and
bodyplethysmography in the detection of early BOS
stages, even though the specificity was low. All of the
above results were confirmed by logistic regression
analysis.
Recognition of advanced BOS stages
To analyze advanced BOS stages, patients were grouped
into BOS 0–1 versus BOS 2–3, although this grouping
led to an even greater imbalance of group sizes (n = 55
versus n = 6). In a discriminant analysis using only spiro-
metric parameters, most of them were significant in
separating the two groups “BOS binary-late”. FEV1 and
FEV1/FVC, both in % predicted, achieved the strongest
separation, whereas FVC % predicted was not signifi-
cant. The positive predictive value of 82.0%, with high
specificity (85.5%) but low sensitivity (50.0%) indicated a
bias due to the unbalanced group sizes. When perform-
ing the analysis with bodyplethysmographic parameters
only, all parameters except for TLC % predicted were
significant in discriminating between the two BOS
groups, with Raw and sRaw as most informative parame-
ters (p < 0.001 each; sRaw: specificity 90.9%, sensitivity
66.7%, positive predictive value 88.5%). To evaluate the
role of the other bodyplethysmographic parameters, the
analysis was repeated without Raw and sRaw. ITGV/
TLC % predicted was the only remaining significant
variable (specificity 76.4%, sensitivity 66.7%, positive pre-
dictive value 75.4%), while the RV/TLC ratio was inferior
Table 1 BMI and age versus BOS stages
Parameter BOS N Mean ± SD
Age (y) 0 19 47.4 ± 15.1
0-p 29 50.8 ± 12.6
1 7 60.4 ± 10.9
2 3 46.7 ± 21.6
3 3 53.7 ± 9.3
Total 61 50.8 ± 13.7
BMI (kg/m2) 0 19 22.3 ± 3.9
0-p 29 24.3 ± 4.7
1 7 22.9 ± 3.9
2 3 23.9 ± 3.3
3 3 21.5 ± 7.6
Total 61 23.4 ± 4.4
The table shows mean values and standard deviations for age and body mass
index (BMI) across the different BOS stages
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to this. The discrimination capability of RV/TLC ratio
versus DLNO % predicted is shown in Fig. 3. The
discriminant analysis using only parameters of diffus-
ing capacity except DLNO/DLCO ratio and DMCO/
Vcap showed that KNO, KCO and DMCO/VA, each
in % predicted, were significant in separating the two
BOS groups. The addition of the DLNO/DLCO ratio
and DMCO/Vcap in the discriminant analysis revealed
DLNO/DLCO ratio as only remaining variable signifi-
cantly separating the “BOS binary-late” groups (specificity
74.5%, sensitivity 66.7%, positive predictive value 73.8%).
The results given above were confirmed by logistic regres-
sion analysis.
Discussion
This study revealed that the diffusing capacity of the lung
for NO allows the early detection of BOS in patients
following BLTx but has no additional value for patients
following SLTx.. Compared to a panel of conventional
lung function measures DLNO was the parameter with
the highest reliability in the detection of early BOS stages.
By contrast, we were not able to show an additional value
of DLNO for the detection of advanced BOS stages within
the limits of a very small number of patients with ad-
vanced BOS stages.
The study population was comprised of 61 patients
with well-balanced gender distribution, and the propor-
tion of SLTx and BLTx patients (n = 19 versus 42) was in
accordance with the international practice favoring BLTx
[1]. The only statistically significant difference between
SLTx and BLTx patients was age, due to the fact that
SLTx was mainly performed in patients with emphy-
sema, whereas BLTx was mostly chosen in younger pa-
tients with cystic fibrosis, in line with international data
[1, 30]. Thus, the study population can be regarded as
representative.
Regarding the early diagnosis of BOS, discriminant
analyses identified FEV1% predicted, Raw and DLNO %
predicted as the parameters from spirometry, bodyplethys-
mography and combined NO-CO diffusing capacity, re-
spectively, which could best differentiate between both
groups. In the competition of these parameters, DLNO %
predicted outperformed the other two parameters which
Table 2 Parameters of spirometry and bodyplethysmography
versus BOS stages
BOS N Mean ± SD p-value
FEV1% predicted 0 19 73.1 ± 20.3 0.004
0-p 29 67.4 ± 16.8
1 7 64.9 ± 8.2
2 3 62.0 ± 5.0
3 3 29.5 ± 9.9
FVC % predicted 0 19 74.7 ± 18.0 0.045
0-p 29 77.9 ± 17.3
1 7 72.2 ± 15.4
2 3 84.6 ± 12.2
3 3 46.6 ± 10.2
FEV1/FVC % predicted 0 19 97.9 ± 15.3 0.002
0-p 29 86.9 ± 14.8
1 7 92.6 ± 20.3
2 3 73.7 ± 11.5
3 3 62.2 ± 11.7
TLC % predicted 0 19 88.4 ± 21.8 0.576
0-p 29 110.1 ± 18.4
1 7 82.2 ± 30.5
2 3 107.2 ± 26.9
3 3 82.7 ± 3.1
ITGV % predicted 0 19 102.9 ± 35.0 0.140
0-p 29 100.1 ± 31.7
1 7 89.8 ± 39.3
2 3 146.4 ± 52.5
3 3 124.3 ± 15.4
RV % predicted 0 19 108.8 ± 49.1 0.233
0-p 29 119.9 ± 54.7
1 7 139.7 ± 83.0
2 3 75.7 ± 31.3
3 3 65.7 ± 12.6
RV/TLC % predicted 0 19 118.1 ± 31.5 0.014
0-p 29 107.9 ± 33.1
1 7 106.9 ± 27.0
2 3 131.9 ± 29.8
3 3 175.0 ± 24.4
Raw (kPa*s*l−1) 0 19 0.27 ± 0.11 < 0.001
0-p 29 0.31 ± 0.10
1 7 0.27 ± 0.09
2 3 0.39 ± 0.11
3 3 0.80 ± 0.19
sRaw (kPa*s) 0 19 0.99 ± 0.65 < 0.001
0-p 29 1.12 ± 0.52
Table 2 Parameters of spirometry and bodyplethysmography
versus BOS stages (Continued)
BOS N Mean ± SD p-value
1 7 0.84 ± 0.36
2 3 1.85 ± 1.06
3 3 3.56 ± 1.17
The table shows mean values and standard deviations. The comparisons
between groups were performed by ANOVA. FEV1 forced expiratory volume in
one second, FVC forced vital capacity, ITGV intrathoracic gas volume, TLC total
lung capacity, RV residual volume, Raw, airway resistance, sRaw specific
airway resistance
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yielded no additional information. Therefore, in line
with our hypothesis, DLNO carried substantial infor-
mation regarding the detection of early BOS stages.
The major pathophysiological changes leading to BOS
include inflammation, repetitive injury of airway epithe-
lia, fibrotic changes and airway remodelling [9]; thus, it
is reasonable to expect an impact on pulmonary func-
tion due to the resulting membrane thickening, which
should be reflected in changes of DLNO. BOS histo-
pathology is in the early stages characterized by inflam-
mation and fibrosis of the airway with sparing of the
surrounding alveoli. Still, this raises the possibility that
the gas transport to and within the alveoli is affected,
which could be detected by a highly sensitive method
assessing gas uptake without major interference with fac-
tors arising from the pulmonary capillaries. In our study
we tested whether DLNO could achieve this task, as a sort
of indirect test of peripheral airway dysfunction.
In diagnosing advanced BOS stages the results were
different, and FEV1 and FEV1/FVC, each in % pre-
dicted, emerged as most informative parameters. This
is reasonable insofar as FEV1 is used for the definition of
these BOS stages. From bodyplethysmography, sRaw and
ITGV/TLC were informative, while in the combined dif-
fusing capacity the DLNO/DLCO ratio remained as sole
differentiating variable. When comparing these parame-
ters to determine their relative predictive value, FEV1/VC
and ITGV/TLC remained informative, while the com-
bined DLNO-DLCO carried no additional value. To facili-
tate the comparison with the literature [10], instead of
ITGV/TLC the ratio RV/TLC was also tested, leading to
similar results.
In the evaluation of all results, the inhomogeneous
group sizes must be considered. The group “BOS-binar-
y-late” was comprised of 6 versus 55 patients, whereas in
the group “BOS-binary-early” the relationship was more
favourable with 13 versus 48 patients. Although the ana-
lysis of the advanced stages was heavily handicapped by
the unbalanced group sizes, the results are consistent
with known data regarding RV/TLC [10], possibly indi-
cating that the relative unimportance of DLNO in this
condition was a valid result.
Table 3 Parameters of diffusing capacity versus BOS stages
BOS N Mean ± SD p-value
DLCO % predicted 0 19 52.0 ± 13.8 0.018
0-p 29 58.0 ± 12.5
1 7 44.3 ± 12.1
2 3 63.8 ± 18.3
3 3 37.9 ± 14.9
KCO % predicted 0 19 75.8 ± 13.2 0.439
0-p 29 84.1 ± 15.0
1 7 77.7 ± 13.7
2 3 87.0 ± 38.9
3 3 77.3 ± 25.8
DLNO % predicted 0 19 44.1 ± 11.8 0.002
0-p 29 47.9 ± 11.0
1 7 35.3 ± 10.2
2 3 48.8 ± 7.1
3 3 22.8 ± 2.2
KNO % predicted 0 19 66.0 ± 11.1 0.014
0-p 29 70.5 ± 9.1
1 7 62.9 ± 12.4
2 3 65.7 ± 19.2
3 3 48.4 ± 4.2
DMCO % predicted 0 19 34.0 ± 10.6 0.004
0-p 29 37.3 ± 11.0
1 7 27.4 ± 9.5
2 3 39.6 ± 5.6
3 3 14.7 ± 0.7
VA % predicted 0 19 67.5 ± 14.7 0.056
0-p 29 67.4 ± 14.1
1 7 55.7 ± 16.7
2 3 71.2 ± 13.0
3 3 46.5 ± 6.4
Vcap % predicted 0 19 69.2 ± 18.9 0.290
0-p 29 75.0 ± 21.4
1 7 58.2 ± 14.5
2 3 75.6 ± 22.8
3 3 93.9 ± 82.6
Vcap/VA % predicted 0 19 106.7 ± 25.6 0.031
0-p 29 116.5 ± 36.5
1 7 111.1 ± 29.4
2 3 115.4 ± 56.5
3 3 201.9 ± 167.0
DMCO/VA % predicted 0 19 52.8 ± 13.1 0.044
0-p 29 57.3 ± 12.0
Table 3 Parameters of diffusing capacity versus BOS stages
(Continued)
BOS N Mean ± SD p-value
1 7 51.9 ± 14.7
2 3 59.3 ± 21.7
3 3 33.1 ± 3.1
The table shows mean values and standard deviations. The comparisons
between groups were performed by ANOVA. DLCO diffusing capacity for
carbon monoxide, DMCO alveolar-capillary membrane diffusing capacity for
carbon monoxide, DLNO diffusing capacity for nitric oxide, KCO transfer factor
for carbon monoxide, KNO transfer factor for nitric oxide; VA alveolar volume,
Vcap pulmonary capillary blood volume
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Thus far, the combined DLNO-DLCO has not been
investigated in patients post LTx for the detection of
BOS. Regarding the early diagnosis DLNO was superior
to all other lung function parameters under study, con-
firming our hypothesis that DLNO is especially sensitive
to changes in peripheral airways which are common in
early stages of BOS. This is remarkable because the defin-
ition of BOS is based not on single measurements but on
the individual time course of spirometric measurements,
while we performed only single measurements expressed
DLNO %predicted
F
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V
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%
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te
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BOS stages
Fig. 2 Detection of BOS. Discrimination capability of DLNO %predicted versus FEV1%predicted. In this figure the five different BOS categories are
indicated separately
D
L
N
O
 %
p
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d
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d
FEV1 %predicted
Grouped BOS stages
Fig. 1 Detection of early BOS. Discrimination capability of DLNO %predicted versus FEV1%predicted in the detection of early BOS. 1 = BOS 0/0-p,
2 = BOS 1/2/3
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as % predicted. The fact that DLNO was superior even
to FEV1 used in the definition of BOS is a hint that the
sensitivity of DLNO could be even greater when used
in individual follow-up measurements. In eight patients,
repeated measurements were available at an average
time interval of 99 days, demonstrating good reprodu-
cibility, but no incident BOS cases occurred during this
time period.
As expected, FEV1 showed a significant capability of
discrimination between BOS stages, as well as RV/TLC,
Raw and sRaw, but only if the combined DLNO-DLCO
was not included. Former investigations revealed that a
high RV/TLC ratio, as indicator of hyperinflation and
air trapping, predicts survival in patients with CLAD
[10]. In our study the RV/TLC ratio was also signifi-
cantly higher in patients with BOS 2–3 as well as in
BOS 1–3, compared to the other BOS stages. Despite
this, the ratio was inferior to DLNO in the detection of
early BOS. Regarding advanced BOS stages the results
for RV/TLC were in line with a previous publication
from our group [10].
The measurement of DLNO-DLCO was performed
before the publication of the European Respiratory Soci-
ety (ERS) technical standards document for the
single-breath CO and NO diffusing capacity [20, 13].
Therefore, the procedure of measurements followed pre-
vious approaches published by van der Lee et al. [31]
and Dressel et al. [21]. Irrespective of this, the measure-
ments were in accordance with recent recommendations
for single-breath DLCO [20, 32] as well as DLNO [13],
taking into account that breath-hold time was within the
range, in which diffusing capacity is not markedly af-
fected by different breath-hold times [33].
The combined DLNO-DLCO allows the non-invasive
discrimination between alterations of gas uptake result-
ing from lung parenchyma versus pulmonary capillary
circulation. This capability has proved useful in differ-
ent diseases such as heart failure [34], liver cirrhosis
[35], pulmonary arterial hypertension [17, 36], chronic
obstructive pulmonary disease [37], cystic fibrosis [22]
and stem cell transplantation [38]. In the present study,
we could extend this range to lung transplant recipi-
ents. Apparently, early structural and/or inflammatory
changes in the lung of patients with BOS deteriorate
alveolar gas uptake as measurable by DLNO, whereas
DLCO, being more dependent on Vcap, seems less
affected.
Additional analyses revealed that DLNO had no value
in recognizing “early BOS” in single-lung transplant pa-
tients, whereas it still showed a significant difference in
double-lung transplant patients (Mann-Whitney-U test,
p = 0.002). This might indicate differences arising from
the different clinical background which led to either
single or double transplantation. Even more likely is
that in single-lung transplant patients the remaining
lung still affected from the background disease domi-
nates the test results thereby preventing the use of
DLNO.
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Fig. 3 Detection of BOS. Discrimination capability of RV/TLC ratio versus DLNO % predicted. In this figure the five different BOS categories are
indicated separately
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Limitations and strengths
The major limitation of our analysis was the small study
cohort; in particular, the low number of patients with
advanced BOS stages. Moreover, the sample size was not
sufficient to find out whether DLNO is even of value in
discriminating between BOS 0 and 0-p; individual
follow-up measurements may be necessary for this. Never-
theless, at least the result for the early detection of BOS
appears plausible enough to motivate larger, multi-center
follow-up studies. This appears feasible, as the measure-
ment of the combined diffusing capacity is standardized,
can be performed simultaneously with the DLCO meas-
urement and does not require specific cooperation or
expertise. In light of the poor prognosis of LTx patients,
any additional non-invasive parameter that could help in
disease monitoring is highly appreciated. As BOS causes
changes in the lung periphery, parameters targeting this
part of the lung are particularly promising, and among
these DLNO appears to be a prime candidate, at least in
patients with double-lung transplants.
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